Introduction
Ykl 40 (Chitinase 3 Like 1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
YKL-40, also known as Chitinase 3-Like 1 (CHI3L1), is a secreted glycoprotein that serves as a biomarker of neuroinflammation and microglial activation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[@bonnehbarkay2012]. Originally discovered as a mammalian homolog of bacterial chitinases, YKL-40 lacks enzymatic activity but functions as a signaling molecule and acute-phase reactant.
Overview
YKL-40 (also known as Chitinase 3-Like 1 or CHI3L1) is a secreted glycoprotein belonging to the chitinase family. It is produced by activated microglia, astrocytes, and other immune cells in response to inflammation. Elevated YKL-40 levels in cerebrospinal fluid (CSF) and blood serve as a biomarker of neuroinflammation and glial activation in neurodegenerative diseases[@mattsson2019].
YKL-40 is being investigated as a diagnostic and prognostic biomarker for Alzheimer's Disease, Parkinson's Disease, and Multiple Sclerosis, with ongoing research exploring its role in disease pathogenesis and therapeutic targeting.
Biochemical Properties
Structure
- Gene: CHI3L1 located on chromosome 1q32.1
- Protein: 383 amino acids, ~40 kDa
- Family: Chitinase-like proteins (glycoside hydrolase family 18)
- Aliases: YKL-40 (N-terminal tyrosine, lysine, leucine, 40 kDa), HC-gp39, BRP-39
Expression
...Introduction
Ykl 40 (Chitinase 3 Like 1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
YKL-40, also known as Chitinase 3-Like 1 (CHI3L1), is a secreted glycoprotein that serves as a biomarker of neuroinflammation and microglial activation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders[@bonnehbarkay2012]. Originally discovered as a mammalian homolog of bacterial chitinases, YKL-40 lacks enzymatic activity but functions as a signaling molecule and acute-phase reactant.
Overview
YKL-40 (also known as Chitinase 3-Like 1 or CHI3L1) is a secreted glycoprotein belonging to the chitinase family. It is produced by activated microglia, astrocytes, and other immune cells in response to inflammation. Elevated YKL-40 levels in cerebrospinal fluid (CSF) and blood serve as a biomarker of neuroinflammation and glial activation in neurodegenerative diseases[@mattsson2019].
YKL-40 is being investigated as a diagnostic and prognostic biomarker for Alzheimer's Disease, Parkinson's Disease, and Multiple Sclerosis, with ongoing research exploring its role in disease pathogenesis and therapeutic targeting.
Biochemical Properties
Structure
- Gene: CHI3L1 located on chromosome 1q32.1
- Protein: 383 amino acids, ~40 kDa
- Family: Chitinase-like proteins (glycoside hydrolase family 18)
- Aliases: YKL-40 (N-terminal tyrosine, lysine, leucine, 40 kDa), HC-gp39, BRP-39
Expression
YKL-40 is expressed by:
- Activated microglia (primary source in CNS)
- Astrocytes (reactive astrocytes in particular)
- Macrophages
- Neutrophils
- Certain neurons (in pathological states)
Role in Neuroinflammation
Physiological Function
While the exact function remains under investigation, YKL-40 is implicated in:
Cell proliferation and survival: Acts as a growth factor for fibroblasts and chondrocytes
Tissue remodeling: Involved in extracellular matrix turnover
Inflammatory responses: Modulates cytokine production and immune cell activity
Angiogenesis: Promotes new blood vessel formationPathological Role in Neurodegeneration
In neurodegenerative diseases, YKL-40 elevation reflects reactive microgliosis and astrogliosis[@perrone2020]:
| Disease | YKL-40 Level | Cellular Source |
|---------|--------------|-----------------|
| Alzheimer's Disease | Elevated (2-3x) | Activated microglia, astrocytes |
| Parkinson's Disease | Elevated (1.5-2x) | Microglia, dopaminergic neurons |
| ALS | Elevated (2-4x) | Activated microglia |
| Multiple Sclerosis | Variable | Reactive astrocytes |
| Frontotemporal Dementia | Elevated | Microglia |
Clinical Significance
Alzheimer's Disease
YKL-40 is considered a marker of innate immune activation in AD[@craigschapiro2011][@hansson2022]:
- Diagnostic utility: Elevated in AD vs. controls (AUC ~0.75-0.85)
- Disease progression: Levels correlate with cognitive decline
- Amyloid correlation: Modest positive correlation with amyloid burden
- Tau correlation: Some studies show association with tau pathology
Parkinson's Disease
In PD, YKL-40 reflects microglial activation and disease severity[@oeckl2022]:
- Elevated CSF YKL-40 in PD vs. healthy controls
- Correlation with motor severity (UPDRS scores)
- Higher levels in PD with dementia vs. PD without dementia
- Potential for progression marker
Differential Diagnosis
YKL-40 helps differentiate neurodegenerative conditions[@heneka2015]:
| Condition | YKL-40 | Utility |
|-----------|--------|---------|
| Alzheimer's Disease | High | Differentiates from FTD |
| Frontotemporal Dementia | Normal-Low | Lower than AD |
| Parkinson's Disease | Moderate | Higher than controls |
| Lewy Body Dementia | Moderate | Similar to PD |
| Vascular Dementia | Variable | Mixed pattern |
Analytical Methods
Measurement
- Assay: ELISA (Enzyme-Linked Immunosorbent Assay)
- Sample: Cerebrospinal fluid (CSF), serum, plasma
- Manufacturer kits: R&D Systems, Mediagnost
Reference Ranges
Typical concentrations (may vary by laboratory):
- CSF: 50-200 ng/mL (controls), >200 ng/mL (elevated)
- Serum: 20-80 ng/mL (controls), >80 ng/mL (elevated)
Biomarker Combinations
YKL-40 is often combined with other neuroinflammation markers[@janelidze2020]:
| Marker | Source | Reflects |
|--------|--------|----------|
| YKL-40 | CSF/Serum | Microglial/astrocytic activation |
| IL-6 | CSF/Serum | Pro-inflammatory cytokine |
| TNF-α | CSF/Serum | Pro-inflammatory cytokine |
| S100B | CSF/Serum | Astrocyte activation |
| NfL) | CSF/Serum | Neurodegeneration |
Research Applications
Biomarker Panels
YKL-40 is incorporated into multi-marker panels[@blennow2023]:
Mermaid diagram (expand to render)
Clinical Trial Use
YKL-40 serves as a target engagement marker for immunomodulatory therapies:
- Anti-inflammatory drug trials
- Microglial modulation therapies
- Disease-modifying approaches targeting neuroinflammation
Therapeutic Implications
Target
YKL-40 itself is not typically a direct therapeutic target, but understanding its regulation provides insight into:
- Microglial activation states
- Therapeutic efficacy of anti-inflammatory interventions
- Disease progression mechanisms
Drug Development
Medications affecting YKL-40:
- NSAIDs: May reduce YKL-40 (chronic use)
- Minocycline: Microglial inhibitor, reduces YKL-40
- Immunomodulators: Variable effects
Future Directions
Emerging research is exploring YKL-40's potential in combination biomarker panels and as a therapeutic target. Recent studies have investigated YKL-40 inhibition as a potential approach to reduce neuroinflammation in Alzheimer's disease and other neurodegenerative conditions. The development of sensitive blood-based assays has expanded the clinical utility of YKL-40 measurement beyond CSF analysis.
Personalized Medicine Applications
YKL-40 levels may help stratify patients based on neuroinflammation burden, potentially guiding personalized treatment strategies. Research is ongoing to establish validated cutoff values for clinical use and to determine optimal sampling protocols.
Background
The study of Ykl 40 (Chitinase 3 Like 1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
External Links
External Links
- [Wikipedia - YKL-40](https://en.wikipedia.org/wiki/YKL-40)
- [UniProt - CHI3L1](https://www.uniprot.org/uniprot/Q8WUJ3)
- [PubMed - YKL-40](https://pubmed.ncbi.nlm.nih.gov/?term=YKL-40+neurodegeneration)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation)
- [Microglia](/cell-types/microglia)
- [Biomarkers of Alzheimer Disease
- Parkinson's Disease Biomarkers](/diseases/alzheimers-disease)
- [Cerebrospinal Fluid (CSF) Biomarkers](/diagnostics/csf-biomarkers)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
References
[Bonneh-Barkay D, et al. (2012). YKL-40 in glutamate excitotoxicity and epilepsy. Epilepsia, 53(1), 25-30, PubMed:22104662 (2012)](https://pubmed.ncbi.nlm.nih.gov/22104662/)
[Perrone F, et al. (2020). Cerebrospinal fluid CHI3L1 (YKL-40) is a marker of neuroinflammation in Alzheimer's disease and multiple sclerosis. Journal of Neuroinflammation, 17(1), 294, PubMed:33213336 (2020)](https://pubmed.ncbi.nlm.nih.gov/33213336/)
[Craig-Schapiro R, et al. (2011). YKL-40: A novel prognostic fluid biomarker for preclinical Alzheimer's disease. Neurology, 77(8), 738-747, PubMed:21753173 (2011)](https://pubmed.ncbi.nlm.nih.gov/21753173/)
[Oeckl P, et al. (2022). YKL-40 in Parkinson's disease and atypical parkinsonism. Movement Disorders, 37(3), 521-531, PubMed:35098547 (2022)](https://pubmed.ncbi.nlm.nih.gov/35098547/)
[Heneka MT, et al. (2015). Neuroinflammation in Alzheimer's disease. Lancet Neurology, 14(4), 388-405, PubMed:25792098 (2015)](https://pubmed.ncbi.nlm.nih.gov/25792098/)
[DOI:10.1038/s41582-019-0221-1](https://doi.org/10.1002/alz.12137)
[DOI:10.1007/s00401-021-02279-0](https://doi.org/10.1186/s13024-023-00638-z)